193 related articles for article (PubMed ID: 23024296)
21. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.
Mullane KM; Miller MA; Weiss K; Lentnek A; Golan Y; Sears PS; Shue YK; Louie TJ; Gorbach SL
Clin Infect Dis; 2011 Sep; 53(5):440-7. PubMed ID: 21844027
[TBL] [Abstract][Full Text] [Related]
22. The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer.
Esmaily-Fard A; Tverdek FP; Crowther DM; Ghantoji SS; Adachi JA; Chemaly RF
Pharmacotherapy; 2014 Nov; 34(11):1220-5. PubMed ID: 25164587
[TBL] [Abstract][Full Text] [Related]
23. Progress with a difficult infection.
Wilcox MH
Lancet Infect Dis; 2012 Apr; 12(4):256-7. PubMed ID: 22321771
[No Abstract] [Full Text] [Related]
24. Management of Clostridium difficile infection: thinking inside and outside the box.
Gerding DN; Johnson S
Clin Infect Dis; 2010 Dec; 51(11):1306-13. PubMed ID: 20979491
[TBL] [Abstract][Full Text] [Related]
25. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection?
Kuijper EJ; Wilcox MH
Clin Infect Dis; 2008 Jul; 47(1):63-5. PubMed ID: 18491959
[No Abstract] [Full Text] [Related]
26. [Recurrent Clostridium difficile enterocolitis].
Bergamin B; Hess T; Jost R; Ballmer PE; Imoberdorf R
Schweiz Med Wochenschr; 2000 Nov; 130(44):1681-4. PubMed ID: 11103440
[TBL] [Abstract][Full Text] [Related]
27. [Antibiotic treatment of clostridial colitis].
Beneš J; Polívková S
Epidemiol Mikrobiol Imunol; 2016; 65(1):15-24. PubMed ID: 27246640
[TBL] [Abstract][Full Text] [Related]
28. Effect of age on treatment outcomes in Clostridium difficile infection.
Louie TJ; Miller MA; Crook DW; Lentnek A; Bernard L; High KP; Shue YK; Gorbach SL
J Am Geriatr Soc; 2013 Feb; 61(2):222-30. PubMed ID: 23379974
[TBL] [Abstract][Full Text] [Related]
29. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.
McFarland LV; Elmer GW; Surawicz CM
Am J Gastroenterol; 2002 Jul; 97(7):1769-75. PubMed ID: 12135033
[TBL] [Abstract][Full Text] [Related]
30. [Feces culture successful therapy in Clostridium difficile diarrhea].
Jorup-Rönström C; Håkanson A; Persson AK; Midtvedt T; Norin E
Lakartidningen; 2006 Nov 15-21; 103(46):3603-5. PubMed ID: 17153868
[No Abstract] [Full Text] [Related]
31. Reply to M.R. Green et al.
Cornely OA; Miller MA; Fantin BR; Mullane KM; Kean Y; Gorbach SL
J Clin Oncol; 2013 Dec; 31(34):4379. PubMed ID: 24166523
[No Abstract] [Full Text] [Related]
32. Treatment of Clostridium difficile infections.
Soriano MM; Johnson S
Infect Dis Clin North Am; 2015 Mar; 29(1):93-108. PubMed ID: 25573676
[TBL] [Abstract][Full Text] [Related]
33. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection.
Bartlett JG
Clin Infect Dis; 2008 May; 46(10):1489-92. PubMed ID: 18419480
[No Abstract] [Full Text] [Related]
34. Metronidazole and vancomycin: equivalence of initial efficacy in CDAD.
Burman LG
Am J Gastroenterol; 2008 Aug; 103(8):2147; author reply 2147. PubMed ID: 18796117
[No Abstract] [Full Text] [Related]
35. Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment.
Johnson S; Schriever C; Patel U; Patel T; Hecht DW; Gerding DN
Anaerobe; 2009 Dec; 15(6):290-1. PubMed ID: 19698797
[TBL] [Abstract][Full Text] [Related]
36. Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin.
Housman ST; Thabit AK; Kuti JL; Quintiliani R; Nicolau DP
Infect Control Hosp Epidemiol; 2016 Feb; 37(2):215-8. PubMed ID: 26592763
[TBL] [Abstract][Full Text] [Related]
37. Meeting the challenge of recurrent Clostridium difficile infection.
Johnson S
J Hosp Med; 2012 Mar; 7 Suppl 3():S11-3. PubMed ID: 22407994
[TBL] [Abstract][Full Text] [Related]
38. [Role of Clostridium difficile infection in the relapse of ulcerative colitis].
Vilalta Castel E; Alcázar Montero MS; Navarro Gaspar C; Gimeno Aranguez M
An Med Interna; 2002 Dec; 19(12):637-9. PubMed ID: 12593034
[TBL] [Abstract][Full Text] [Related]
39. Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting.
Venugopal AA; Riederer K; Patel SM; Szpunar S; Jahamy H; Valenti S; Shemes SP; Khatib R; Johnson LB
Scand J Infect Dis; 2012 Apr; 44(4):243-9. PubMed ID: 22077148
[TBL] [Abstract][Full Text] [Related]
40. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS
Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
